Axsome Therapeutics (AXSM) Stock Forecast & Price Target

Axsome Therapeutics is compelling fundamentally because Auvelity has become a scalable commercial franchise with strong momentum in major depressive disorder and a newly approved Alzheimer’s disease agitation indication that addresses a large unmet need, supported by near-100% Medicare Part D coverage, >85% of covered lives without prior authorization, and 126% NBRx growth in patients 65+ over the first eight weeks. The company also benefits from a de-risked CNS-focused pipeline and existing commercial infrastructure, with 2Q26 Auvelity net sales of $180.3M (+51% y/y), ~266k prescriptions (+34% y/y), and 69,000 cumulative unique prescribers, while Symbravo launch progress and additional late-stage readouts create further optionality without requiring major incremental infrastructure spend. Despite risks around Auvelity concentration, generic-heavy competition, and future IRA pressure, the underlying thesis remains positive because the company is converting a clinically differentiated asset into durable revenue growth across large underserved CNS markets with multiple shots on goal.

Axsome Therapeutics is attractive on the surface because Auvelity and the broader pipeline have clear near-term catalysts, but the negative case centers on diminishing commercial breadth, slowing growth, and increasing dependence on execution rather than de-risking alone. Auvelity’s MDD franchise already had about 980k FY26E scripts against a roughly 350M FY26E market, and the company’s own data suggest prescriber reach may be nearing saturation at about 69,000 prescribers, leaving future expansion reliant on deeper prescribing, persistence, and earlier-line use that may be harder to sustain. That concern is reinforced by decelerating year-over-year MDD growth from 46% in 3Q25 to 42% in 4Q25, 35% in 1Q26, and 34% in 2Q26, while competition is intensifying for Sunosi in narcolepsy/EDS and the pipeline, though clinically de-risked, still requires successful execution across multiple indications before it can offset any slowdown in the core franchise.